Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?

• Published in: Clinical cancer research Vol. 15; no. 19; pp. 6106 - 6112
• Main Authors: Ali, Majid, Telfer, Brian A., McCrudden, Cian, O'Rourke, Martin, Thomas, Huw D., Kamjoo, Marzieh, Kyle, Suzanne, Robson, Tracy, Shaw, Chris, Hirst, David G., Curtin, Nicola J., Williams, Kaye J.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.10.2009
• Subjects: AG014699; Animals; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Azulenes - administration & dosage; Azulenes - pharmacology; Benzodiazepines - administration & dosage; Benzodiazepines - pharmacology; Biological and medical sciences; Blood Vessels - drug effects; Blood Vessels - physiopathology; Capillary Permeability - drug effects; Dacarbazine - administration & dosage; Dacarbazine - analogs & derivatives; Drug Resistance, Neoplasm - drug effects; Female; HT29 Cells; Humans; Indoles - administration & dosage; Indoles - pharmacology; Medical sciences; Mice; Mice, Nude; Neoplasms - blood supply; Neoplasms - drug therapy; Neoplasms - pathology; PARP; Pharmacology. Drug treatments; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; therapeutic; Tumor Cells, Cultured; vasoactivity; Xenograft Model Antitumor Assays; NAD; In vivo; Enzyme; Transferases; Glycosyltransferases; ADP-ribosyltransferase; Inhibitor; Small molecule; Pentosyltransferases
• ISSN: 1078-0432; 1557-3265; 1557-3265
• DOI: 10.1158/1078-0432.CCR-09-0398

Purpose: Poly(ADP-ribose) polymerase (PARP) plays an important role in DNA repair, and PARP inhibitors can enhance the activity of DNA-damaging agents in vitro and in vivo . AG014699 is a potent PARP inhibitor in phase II clinical development. However, the range of therapeutics with which AG014699 could interact via a DNA-repair based mechanism is limited. We aimed to investigate a novel, vascular-based activity of AG014699, underlying in vivo chemosensitization, which could widen its clinical application. Experimental Design: Temozolomide response was analyzed in vitro and in vivo . Vessel dynamics were monitored using “mismatch” following the administration of perfusion markers and real-time analysis of fluorescently labeled albumin uptake in to tumors established in dorsal window chambers. Further mechanistic investigations used ex vivo assays of vascular smooth muscle relaxation, gut motility, and myosin light chain kinase (MLCK) inhibition. Results: AG014699 failed to sensitize SW620 cells to temozolomide in vitro but induced pronounced enhancement in vivo . AG014699 (1 mg/kg) improved tumor perfusion comparably with the control agents nicotinamide (1 g/kg) and AG14361 (forerunner to AG014699; 10 mg/kg). AG014699 and AG14361 relaxed preconstricted vascular smooth muscle more potently than the standard agent, hydralazine, with no impact on gut motility. AG014699 inhibited MLCK at concentrations that relaxed isolated arteries, whereas AG14361 had no effect. Conclusion: Increased vessel perfusion elicited by AG014699 could increase tumor drug accumulation and therapeutic response. Vasoactive concentrations of AG014699 do not cause detrimental side effects to gut motility and may increase the range of therapeutics with which AG014699 could be combined with for clinical benefit. (Clin Cancer Res 2009;15(19):6106–12)